News
FBIO
--
0.00%
--
8-K: Fortress Biotech, Inc.
(EDGAR Online via COMTEX) -- 0001429260 false 0001429260 2021-02-24 2021-02-24 0001429260 us-gaap:CommonStockMember 2021-02-24 2021-02-24...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 10h ago
Making A List Of Penny Stocks To Watch This Week? 4 To Know
Feb 24, 2021 (Penny Stocks via COMTEX) -- Looking For Penny Stocks to Watch? Check Out These 4 While February has not been the best month for blue-chip...
Penny Stocks · 14h ago
Penny Stocks To Buy According To Analysts & Price Forecasts Up To 439%
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Rate These Penny Stocks A Buy Right Now Finding the best penny stocks to buy right now can be a tall...
Penny Stocks · 14h ago
Fortress Biotech (FBIO) Receives a Buy from B.Riley Financial
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Fortress Biotech (FBIO) today and set a price target of $8.00. The company's shares
SmarterAnalyst · 19h ago
Fortress Biotech Partner Cyprium Therapeutics to Sell Proprietary Rights for CUTX-101 to Sentynl Therapeutics
MT Newswires · 19h ago
Fortress Biotech's Partner Offloads CUTX-101 To Sentynl Therapeutics
Benzinga · 21h ago
BRIEF-Cyprium Therapeutics And Sentynl Therapeutics, Sign Development And Asset Purchase Agreement For Cyprium Therapeutics' Copper Histidinate Product Candidate For Treatment Of Menkes Disease
reuters.com · 22h ago
Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics' Copper Histidinate Product Candidate for Treatment of Menkes Disease
Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties
GlobeNewswire · 22h ago
Fortress Biotech CEO Explains The Company's Three-Step Business Model
Fortress Biotech was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers ...
Benzinga · 1d ago
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board
GlobeNewswire · 2d ago
BRIEF-Aevitas Therapeutics Appoints Markus Peters As Chief Executive Officer
reuters.com · 2d ago
Aevitas TherapeuticsNames Markus Peters CEO
Aevitas TherapeuticsNames Markus Peters CEO
Dow Jones · 2d ago
Press Release: Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
Dow Jones · 2d ago
Global Calcitonin Gene Related Peptide Type 1 Receptor Market 2021: In-Depth Industry Analysis on Size, Cost Structure, Share, Revenue, Influences Factors and Prominent Key Players till 2027
Feb 15, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Calcitonin Gene Related...
The Express Wire · 02/15 05:23
CAR T Cell Therapy Market Size, Growth, Trends and Forecast to (2020-2026)
Feb 08, 2021 (Market Insight Reports) -- The CAR T Cell Therapy market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR...
Market Insight Reports · 02/08 07:12
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTE...
GlobeNewswire · 02/02 12:30
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID)
FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial Company plans to enroll first patient in MB-107 pivotal trial in the second quarter of 2021 Clinical outcomes in investigator-IND XSCID trials continue to show compelling efficacy WORCESTE...
GlobeNewswire · 02/02 12:30
Immune Check Point Inhibitor Market 2021 with Top Countries Data, Trends, Share, Size, Industry Growth, Supply and 2025 Manufacturers Analysis Research Report
Jan 29, 2021 (The Expresswire) -- Worldwide “Immune Check Point Inhibitor Market” research report 2021-2025 gives most upcoming industry information on the...
The Express Wire · 01/29 09:13
Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market to Witness a Notable CAGR During 2021-2029; Growing Number of Head and Neck Cancer Cases to Create Opportunities for Market Growth
Jan 18, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment and Drugs Market: Global...
AmericaNewsHour · 01/18 05:10
When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Fortress Biotech, Inc.'s...
Simply Wall St. · 01/16 07:58
Webull provides a variety of real-time FBIO stock news. You can receive the latest news about Fortress Biotech through multiple platforms. This information may help you make smarter investment decisions.
About FBIO
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.